Amgen Inc. Common StockAMGN
Closing prices as of Oct 26, 2026Updated once daily after the US close — not a live quote.

$444.00

+6.87% past month

Notable price movement

  • Oct 26, 2026

    $444.63+1.22%

    Amgen announced the appointment of David W. Gibbs to its Board of Directors, effective immediately . The shares closed up 1.22% on the day, though the headline does not say the appointment drove the move.

  • Oct 23, 2026

    $439.26-1.79%

    Amgen closed down 1.79%, while comparable biological products companies moved -0.65% on average, with 5 of 6 falling . The decline was larger than the cohort's average move, so it was only partly shared. The one headline held concerned a different company, BeOne Medicines, and does not explain Amgen's move .

  • Oct 22, 2026

    $447.28+2.04%

    Amgen rose 2.04% while comparable biological products companies moved -2.06% on average, with 3 of 6 falling and 3 rising . The cohort average was pulled down by a 17.57% drop in MRNA, and the move was not shared by the group as a whole .

  • Oct 21, 2026

    $438.34-0.14%

  • Oct 20, 2026

    $438.94+3.29%

    Comparable biological products companies rose 4.20% on average, with all 6 of 6 higher, so Amgen's gain moved alongside its cohort . Seeking Alpha reported that Amgen and AstraZeneca announced phase 3 results for Tezspire in eosinophilic esophagitis, with the trial reaching histologic remission and reducing dysphagia, sustained to week 52 .

  • Oct 19, 2026

    $424.94-1.75%

    Amgen fell 1.75% while comparable biological products companies moved up 1.01% on average, with 5 of 6 rising . The decline was therefore not shared by the cohort as a whole.

  • Oct 16, 2026

    $432.49-0.35%

    Amgen closed down 0.35%, a smaller decline than its cohort. Comparable listed companies in biological products fell 2.92% on average, with all 6 of 6 falling . The company's shares therefore fell less than the group.

Closing prices for AMGN. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Recent news

Pr Newswire21 hours agoAMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORSSeeking Alpha18 hours agoTCW Concentrated Large Cap Growth Fund Q3 2026 Winners, Laggards, Buys & SellsThe Motley Fool2 days agoAmgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy?Pr Newswire6 days agoAMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026Seeking Alpha1 day agoRoche lung cancer drug extends survival by nearly six months in late-stage trialThe Motley Fool3 days agoAmgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.

Prices and financial data are historical and provided for research only. Not investment advice.

AMGN — Amgen Inc. Common Stock price, financials and news - Amaltash